Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update
AC Immune SAApril 28, 2021 GMT
Reported potent interim immunogenicity results for anti-pTau Alzheimer’s vaccine in ongoing Phase 1b/2a study, which support further development into Phase 2/3
Initiated first-in-human clinical study for next-generation alpha-synuclein PET diagnostic with results expected in Q3 2021
Advanced multiple candidates targeting the NLRP3 inflammasome pathway for CNS and non-CNS indications
Strong financial position of CHF 216.1 million in cash ensures the Company is fully financed through at least Q1 2024
LAUSANNE, Switzerland, April 28, 2021 (GLOBE NEWSWIRE) AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2021. The Co